文献速递消化、代谢与肾脏急症

治疗剂量对乙酰氨基酚所致ALT升高的相关遗传变异

Genetic variants associated with ALT elevation from therapeutic acetaminophen.
PubMed 文献 · Clin Toxicol (Phila) · 2022-09-14
一句话结论治疗剂量对乙酰氨基酚所致ALT升高仅与SULT1E1基因变异及年龄>50岁相关,多数代谢或免疫介导DILI相关基因未显示关联。

该研究对服用治疗剂量对乙酰氨基酚(4克/日,最长16天)的患者进行遗传学分析,检测20个与对乙酰氨基酚代谢或免疫介导DILI相关的基因,以治疗期间最高ALT为主要结局。192例受试者中,年龄>50岁是唯一与最高ALT升高相关的临床因素;SULT1E1基因变异与最高ALT相关,且该关联由基因内多个变异的累加效应所致,非单一变异驱动。其他基因均未显示与最高ALT升高相关。作者结论认为,治疗剂量对乙酰氨基酚所致ALT升高与本队列中多数代谢或免疫介导DILI相关基因变异无关,SULT1E1多态性的作用需进一步研究。

要点

  • 治疗剂量对乙酰氨基酚(4克/日,最长16天)所致最高ALT升高仅与SULT1E1基因变异相关,且为多个变异累加效应,非单一变异驱动。
  • 年龄>50岁是唯一与最高ALT升高相关的临床因素(192例受试者中)。
  • 20个候选基因中,除SULT1E1外,其余与对乙酰氨基酚代谢或免疫介导DILI相关的基因均未显示与最高ALT升高相关。
  • 作者结论:治疗剂量对乙酰氨基酚所致ALT升高与本队列中多数相关基因变异无关,SULT1E1多态性的作用需进一步研究。

适用人群与场景

  • 服用治疗剂量对乙酰氨基酚4克/日、最长16天的患者(192例纳入遗传学分析;136例(70.8%)女性,133例(69.2%)白人种族,中位年龄34岁(IQR:26,46))。

研究设计与关键结果

  • 研究类型:遗传学分析(对治疗剂量对乙酰氨基酚服用者进行候选基因区域分析);样本量192例;干预:服用治疗剂量对乙酰氨基酚4克/日,最长16天;主要结局:治疗期间最高ALT。
  • 年龄>50岁是唯一与最高ALT升高相关的临床因素。
  • SULT1E1基因变异与最高ALT相关,该关联由基因内多个变异的累加效应所致,非单一变异驱动;本队列中其他基因均未显示与最高ALT升高相关。

证据类型、等级与局限

  • 证据类型:遗传学分析(候选基因区域分析)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论:治疗剂量对乙酰氨基酚所致ALT升高与本队列中多数与对乙酰氨基酚代谢或免疫介导DILI相关的基因变异无关;SULT1E1多态性在治疗剂量对乙酰氨基酚所致ALT升高中的作用需进一步研究。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Several studies have suggested genetic variants associated with acetaminophen induced liver injury (DILI) following overdose. Genetic variation associated with acetaminophen-induced alanine aminotransferase elevation during therapeutic dosing has not been examined.

METHODS: We performed genetic analyses on patients that ingested therapeutic doses of 4 grams of acetaminophen for up to 16 days. We examined 20 genes previously implicated in the metabolism of acetaminophen or the development of immune-mediated DILI using the Illumina Multi-Ethnic Global Array 2. Autosomes were aligned and imputed using TOPMed. A candidate gene region analysis was performed by testing each gene individually using linkage disequilibrium (LD) pruned variants with the adaptive sum of powered scores (aSPU) test from the aSPU R package. The highest measured ALT during therapy, the maximum ALT, was used as the outcome.

RESULTS: 192 subjects taking therapeutic APAP were included in the genetic analysis. 136 (70.8%) were female, 133 (69.2%) were Caucasian race, and the median age was 34 years (IQR: 26, 46). Age > 50 years was the only clinical factor associated with maximum ALT increase. Variants in SULT1E1, the gene responsible for Sulfotransferase Family 1E Member 1 enzyme production, were associated with maximum ALT. No single variant drove this association, but rather the association was due to the additive effects of numerous variants within the gene. No other genes were associated with maximum ALT increase in this cohort.

CONCLUSION: Acetaminophen induced ALT elevation at therapeutic doses was not associated with variation in most genes associated with acetaminophen metabolism or immune-induced DILI in this cohort. The role of SULT1E1 polymorphism in acetaminophen-induced elevated ALT needs further examination.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Monte AA, Arriaga Mackenzie I, Pattee J, et al. Genetic variants associated with ALT elevation from therapeutic acetaminophen. Clin Toxicol (Phila). 2022. PMID: 36102175. doi:10.1080/15563650.2022.2117053

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。